Patents
Literature
6 results about "Timolol" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (e.g., ocular hypertension).
Transparent composite eye drop containing carbonic anhydrase inhibitors and timolol and preparation method therefor
PCT designated stageWO2025239614A1Organic active ingredientsSenses disorderCyclodextrinPharmaceutical medicine
The present invention relates to: a transparent composite eye drop containing carbonic anhydrase inhibitors, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent; and a preparation method therefor.
Owner:HUONS
Aqueous liquid preparation
To provide formulation technology concerning an aqueous liquid preparation comprising brinzolamide and / or a salt thereof.SOLUTION: An aqueous liquid preparation containing brinzolamide and / or a salt thereof, 0.08-0.12 w / v% brimonidine tartrate, and timolol and / or a salt thereof.SELECTED DRAWING: None
Owner:SENJU PHARMA CO LTD
Pharmaceutical compositions comprising timolol
The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.
Owner:NOVALIQ GMBH
Fixed dose combination of brimonidine and timolol
Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.
Owner:ALLERGAN INC
Formulations for delivery of a colloidal prodrug to lower intraocular pressure (IOP) for a prolonged time
PCT designated stageWO2026112747A1Organic active ingredientsSenses disorderOphthalmologyPharmaceutical Substances
The present disclosure relates to colloidal drug aggregates (CDAs) that are further embedded in hydrogels for sustained local delivery. Preferred drugs include beta-blocker prodrugs and ROCK inhibitors for use in treating glaucoma. In particularly preferred embodiments, the CDAs comprise prodrugs of timolol or netarsudil in combination with phospholipid stabilizers. Preferred hydrogels include hyaluronan crosslinked using an oxime bond.
Owner:DANG MICKAEL +1
Transparent composite eye drops containing carbonic anhydrase inhibitor and timolol and preparation method thereof
The present invention relates to a transparent composite eye drop containing a carbonic anhydrase inhibitor, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent, and to a method for preparing the same. The present invention relates to a transparent composite eye drop containing a carbonic anhydrase inhibitor, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent.
Owner:HUONS